Background {#cesec10}
==========

Feline infectious peritonitis virus (FIPV), a feline coronavirus (FCoV) of the family *Coronaviridae*, causes a fatal disease called feline infectious peritonitis (FIP) in wild and domestic cat species. Several organs, including the liver, lungs, spleen, serosae, kidneys, eyes, and central nervous system, are affected in cats that develop FIP, and the formation of lesions in these organs is accompanied by necrosis and pyogenic granulomatous inflammation. Pleural effusion and ascitic fluid have been reported to accumulate in some cats. FCoVs are classified into two serotypes: type I and II FCoV, based on differences in the amino acid sequence of S protein. Several antiviral agents have been reported for FIPV. These drugs have been confirmed to reduce the proliferation of FIPV, but they are not commercially distributed as veterinary drugs. We previously found that itraconazole (ICZ), which is used in veterinary medicine, reduces the proliferation of type I FIPV. However, the therapeutic effects of ICZ in cats with FIP remain unclear.

Objectives {#cesec20}
==========

•To evaluate whether adalimumab (ADA), an anti-human-TNF-alpha mAb, has neutralizing activity against fTNF-alpha.•To evaluate the therapeutic effects of ADA and ICZ on FIP by administering them to cats with experimentally induced FIP.

Procedure {#cesec30}
=========

Ten specific pathogen-free (SPF) cats were inoculated intraperitoneally with type I FIPV KU-2. To the cats that developed FIP, ADA was administered twice between day 0 and day 4 after the start of treatment. ICZ was orally administered daily from day 0 after the start of treatment.

Results {#cesec40}
=======

Two of three cats showed improvements in FIP clinical symptoms and blood chemistry test results, an increase in the peripheral blood lymphocyte count, and a decrease in the plasma alpha 1-AGP level were observed after the beginning of treatment. One of the cats failed to respond to treatment and was euthanized, although the viral gene level in ascites temporarily decreased after the start of treatment. ADA was found to have dose-dependent neutralizing activity against rfTNF-alpha.

Author Conclusions {#cesec50}
==================

Recently, GC-376, a 3C-like protease inhibitor, and GS-441524, a nucleoside analog, have been developed as drugs to inhibit the proliferation of FIPV. GC-376 and GS-441524 are efficacious drugs that produce therapeutic effects in 30 to 80% of FIP cats. Although these drugs are expected to be useful as treatments for FIP, they have not been approved. Therefore, no drugs are available in clinical practice for the treatment of FIP. In this study, we demonstrated that the combined use of ADA and ICZ, which are presently available to veterinarians, is effective for the treatment of FIP. We consider these drugs to be a treatment option until antiviral drugs such as GC-376 and GS-441524 become available. In addition, these antiviral drugs exert therapeutic effects on FIP by mechanisms different from those of ADA and ICZ. In the future, the evaluation of the therapeutic effects of their concomitant use may aid in the development of more effective treatments for FIP.
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Nine figures, 32 references.

Editor Annotation {#cesec70}
=================

This is a groundbreaking study in that the researchers have found a combination of drugs that may possibly cure FIP, or at least cause it to go into remission in some cats. No treatments to date have definitively been shown to do this. The study of potential treatment options for FIP is terribly important, as this is a heartbreaking, rapidly fatal disease with no known cure and very little available supportive care. The study is very well done and builds on earlier well done FIP research done by the same researchers and others. Limits to the study include the small numbers involved. The two cats who improved became clinically normal, which is very promising. However, we only know the short-term outcome, as they were euthanized 60 days into the study. Also, although itraconazole is readily available to veterinary teams and affordable for clients, anti-human-TNF-alpha antibody (adalimubab, Humira) would likely be cost prohibitive for veterinary clients. There is no generic alternative available for this drug. The researchers conclude that this is a treatment option that can be used clinically, but while the research is indeed very encouraging, larger scope testing must be done and more affordable sources of adalimubab found before this treatment can practically be used for feline patients with FIP in a clinical setting. (SF)
